178 related articles for article (PubMed ID: 27612426)
1. Inhibition of nuclear factor-κB signaling suppresses Spint1-deletion-induced tumor susceptibility in the ApcMin/+ model.
Kawaguchi M; Yamamoto K; Kanemaru A; Tanaka H; Umezawa K; Fukushima T; Kataoka H
Oncotarget; 2016 Oct; 7(42):68614-68622. PubMed ID: 27612426
[TBL] [Abstract][Full Text] [Related]
2. Hepatocyte growth factor activator inhibitor type 1 is a suppressor of intestinal tumorigenesis.
Hoshiko S; Kawaguchi M; Fukushima T; Haruyama Y; Yorita K; Tanaka H; Seiki M; Inatsu H; Kitamura K; Kataoka H
Cancer Res; 2013 Apr; 73(8):2659-70. PubMed ID: 23447577
[TBL] [Abstract][Full Text] [Related]
3. Protease-activated receptor-2 accelerates intestinal tumor formation through activation of nuclear factor-κB signaling and tumor angiogenesis in Apc
Kawaguchi M; Yamamoto K; Kataoka H; Izumi A; Yamashita F; Kiwaki T; Nishida T; Camerer E; Fukushima T
Cancer Sci; 2020 Apr; 111(4):1193-1202. PubMed ID: 31997435
[TBL] [Abstract][Full Text] [Related]
4. Membrane-bound serine protease inhibitor HAI-1 is required for maintenance of intestinal epithelial integrity.
Kawaguchi M; Takeda N; Hoshiko S; Yorita K; Baba T; Sawaguchi A; Nezu Y; Yoshikawa T; Fukushima T; Kataoka H
Am J Pathol; 2011 Oct; 179(4):1815-26. PubMed ID: 21840293
[TBL] [Abstract][Full Text] [Related]
5. Targeting of nuclear factor kappaB Pathways by dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: antitumor and antiangiogenic potential in vivo.
Matsumoto G; Namekawa J; Muta M; Nakamura T; Bando H; Tohyama K; Toi M; Umezawa K
Clin Cancer Res; 2005 Feb; 11(3):1287-93. PubMed ID: 15709200
[TBL] [Abstract][Full Text] [Related]
6. Stat6 Promotes Intestinal Tumorigenesis in a Mouse Model of Adenomatous Polyposis by Expansion of MDSCs and Inhibition of Cytotoxic CD8 Response.
Jayakumar A; Bothwell ALM
Neoplasia; 2017 Aug; 19(8):595-605. PubMed ID: 28654863
[TBL] [Abstract][Full Text] [Related]
7. Epimorphin deletion inhibits polyposis in the Apcmin/+ mouse model of colon carcinogenesis via decreased myofibroblast HGF secretion.
Swietlicki EA; Bala S; Lu J; Shaker A; Kularatna G; Levin MS; Rubin DC
Am J Physiol Gastrointest Liver Physiol; 2013 Oct; 305(8):G564-72. PubMed ID: 23886856
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1.
Takatsuna H; Asagiri M; Kubota T; Oka K; Osada T; Sugiyama C; Saito H; Aoki K; Ohya K; Takayanagi H; Umezawa K
J Bone Miner Res; 2005 Apr; 20(4):653-62. PubMed ID: 15765185
[TBL] [Abstract][Full Text] [Related]
9. A novel NF-κB inhibitor, dehydroxymethylepoxyquinomicin, ameliorates inflammatory colonic injury in mice.
Funakoshi T; Yamashita K; Ichikawa N; Fukai M; Suzuki T; Goto R; Oura T; Kobayashi N; Katsurada T; Ichihara S; Ozaki M; Umezawa K; Todo S
J Crohns Colitis; 2012 Mar; 6(2):215-25. PubMed ID: 22325176
[TBL] [Abstract][Full Text] [Related]
10. A novel NF-kappaB inhibitor DHMEQ selectively targets constitutive NF-kappaB activity and induces apoptosis of multiple myeloma cells in vitro and in vivo.
Watanabe M; Dewan MZ; Okamura T; Sasaki M; Itoh K; Higashihara M; Mizoguchi H; Honda M; Sata T; Watanabe T; Yamamoto N; Umezawa K; Horie R
Int J Cancer; 2005 Mar; 114(1):32-8. PubMed ID: 15523684
[TBL] [Abstract][Full Text] [Related]
11. NF-kappaB inhibitor dehydroxymethylepoxyquinomicin suppresses osteoclastogenesis and expression of NFATc1 in mouse arthritis without affecting expression of RANKL, osteoprotegerin or macrophage colony-stimulating factor.
Kubota T; Hoshino M; Aoki K; Ohya K; Komano Y; Nanki T; Miyasaka N; Umezawa K
Arthritis Res Ther; 2007; 9(5):R97. PubMed ID: 17892600
[TBL] [Abstract][Full Text] [Related]
12. Anoikis induction and inhibition of peritoneal metastasis of pancreatic cancer cells by a nuclear factor-κB inhibitor, (-)-DHMEQ.
Sato M; Nakanishi K; Haga S; Fujiyoshi M; Baba M; Mino K; ; Niwa H; Yokoo H; Umezawa K; Ohmiya Y; Kamiyama T; Todo S; Taketomi A; Ozaki M
Oncol Res; 2013; 21(6):333-43. PubMed ID: 25198663
[TBL] [Abstract][Full Text] [Related]
13. Dehydroxymethylepoxyquinomicin, a novel nuclear Factor-kappaB inhibitor, enhances antitumor activity of taxanes in anaplastic thyroid cancer cells.
Meng Z; Mitsutake N; Nakashima M; Starenki D; Matsuse M; Takakura S; Namba H; Saenko V; Umezawa K; Ohtsuru A; Yamashita S
Endocrinology; 2008 Nov; 149(11):5357-65. PubMed ID: 18653704
[TBL] [Abstract][Full Text] [Related]
14. Defect of hepatocyte growth factor activator inhibitor type 1/serine protease inhibitor, Kunitz type 1 (Hai-1/Spint1) leads to ichthyosis-like condition and abnormal hair development in mice.
Nagaike K; Kawaguchi M; Takeda N; Fukushima T; Sawaguchi A; Kohama K; Setoyama M; Kataoka H
Am J Pathol; 2008 Nov; 173(5):1464-75. PubMed ID: 18832587
[TBL] [Abstract][Full Text] [Related]
15. DHMEQ, a novel NF-kappaB inhibitor, induces apoptosis and cell-cycle arrest in human hepatoma cells.
Nishimura D; Ishikawa H; Matsumoto K; Shibata H; Motoyoshi Y; Fukuta M; Kawashimo H; Goto T; Taura N; Ichikawa T; Hamasaki K; Nakao K; Umezawa K; Eguchi K
Int J Oncol; 2006 Sep; 29(3):713-9. PubMed ID: 16865289
[TBL] [Abstract][Full Text] [Related]
16. Pleiotropic potential of dehydroxymethylepoxyquinomicin for NF-κB suppression via reactive oxygen species and unfolded protein response.
Nakajima S; Kato H; Gu L; Takahashi S; Johno H; Umezawa K; Kitamura M
J Immunol; 2013 Jun; 190(12):6559-69. PubMed ID: 23690471
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of macrophage activation and phagocytosis by a novel NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin.
Suzuki E; Umezawa K
Biomed Pharmacother; 2006 Nov; 60(9):578-86. PubMed ID: 16978829
[TBL] [Abstract][Full Text] [Related]
18. Effect of a small molecule inhibitor of nuclear factor-kappaB nuclear translocation in a murine model of arthritis and cultured human synovial cells.
Wakamatsu K; Nanki T; Miyasaka N; Umezawa K; Kubota T
Arthritis Res Ther; 2005; 7(6):R1348-59. PubMed ID: 16277688
[TBL] [Abstract][Full Text] [Related]
19. Induction of thyroid cancer cell apoptosis by a novel nuclear factor kappaB inhibitor, dehydroxymethylepoxyquinomicin.
Starenki DV; Namba H; Saenko VA; Ohtsuru A; Maeda S; Umezawa K; Yamashita S
Clin Cancer Res; 2004 Oct; 10(20):6821-9. PubMed ID: 15501958
[TBL] [Abstract][Full Text] [Related]
20. Antitumor effect of dehydroxymethylepoxyquinomicin, a small molecule inhibitor of nuclear factor-κB, on glioblastoma.
Fukushima T; Kawaguchi M; Yorita K; Tanaka H; Takeshima H; Umezawa K; Kataoka H
Neuro Oncol; 2012 Jan; 14(1):19-28. PubMed ID: 21968049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
